1,3-Oxazol-2(5H)-one → 3-{4-[4-(3,5,6-Trimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}oxazolidin-2-one
반응식
I[C:2]1[CH:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][N:13]([C:16]3[C:21]([CH3:22])=[CH:20][C:19]([CH3:23])=[C:18]([CH3:24])[N:17]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[O:25]1[CH2:29][CH:28]=[N:27][C:26]1=[O:30]>>[CH3:22][C:21]1[C:16]([N:13]2[CH2:14][CH2:15][N:10]([C:8]([C:5]3[CH:6]=[CH:7][C:2]([N:27]4[CH2:28][CH2:29][O:25][C:26]4=[O:30])=[CH:3][CH:4]=3)=[O:9])[CH2:11][CH2:12]2)=[N:17][C:18]([CH3:24])=[C:19]([CH3:23])[CH:20]=1참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Example 149 and using (4-iodophenyl)[4-(3,5,6-trimethylpyridin-2-yl)piperazin-1-yl]methanone (435 mg) described in Preparation Example 176 and oxazolin-2-one (104 mg), the title compound (118 mg) was obtained.
후처리
- customBy reaction and treatment in the same manner as in Example 149